Loading...
01/10 18:21
Loading...
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
The earnings call presents a mixed but overall positive outlook. Despite a 4% revenue decrease due to customer transition, organic growth is strong at 15%. EPS growth is solid at 9%, and gross margins have improved. Share repurchase and dividend plans are robust, and specialty business growth is promising. However, raw material shortages and economic factors pose risks. The Q&A reveals confidence in handling these challenges, with management raising guidance due to strong demand. The positive aspects outweigh the negatives, suggesting a positive stock price reaction.
Total Company Revenue $52 billion, decreased 4% year-over-year; adjusted for customer transition, increased 15% due to strong organic revenue growth.
Total Company Gross Margin Increased 9%, driven by positive trends in both Brands and Generics in the Pharma segment.
SG&A Expenses Increased by $91 million or 8% year-over-year; approximately half of this increase was due to higher health and welfare employee costs.
Operating Earnings $625 million, 12% higher than last year.
Interest and Other Expenses Increased $15 million to $27 million, primarily due to lower interest income from anticipated lower cash balances.
Effective Tax Rate 23%, up 2 percentage points due to the non-repetition of positive discrete items from the prior year.
Average Diluted Shares Outstanding 245 million, 2% lower than a year ago.
EPS $1.88, growth of 9%.
Pharma Segment Revenue $48 billion, decreased 5% due to customer transition; excluding that, revenue increased 16% driven by brand and specialty pharmaceutical sales.
Pharma Segment Profit $530 million, increased 16% driven by higher contributions from Brand and Specialty Products.
GMPD Segment Revenue $3.1 billion, increased 3% driven by volume growth from existing customers.
GMPD Segment Profit Decreased to $8 million due to a $17 million increase in health and welfare costs.
Other Businesses Revenue $1.2 billion, increased 13% due to growth across all three businesses.
Other Businesses Segment Profit Increased by 8%, driven by the performance of OptiFreight Logistics.
Cash Position $2.9 billion, includes $200 million earmarked for November debt maturity.
Adjusted Free Cash Flow A use of $1.4 billion for the quarter, better than expectations.
CapEx Investment $90 million invested back into the businesses.
Shareholder Returns Returned approximately $500 million to shareholders through share repurchase and dividends.
Acquisition Agreement Reached an agreement to acquire Integrated Oncology Network for $1.1 billion.
New Product Launches: The company is preparing for the launch of the next-generation Kendall Compression device in the back half of the fiscal year.
Acquisition: Cardinal Health reached an agreement to acquire Integrated Oncology Network for $1.1 billion, aimed at improving cancer care in underserved communities.
Product Expansion: The demand for the newest Kangaroo OMNI Enteral Feeding Pump has continued to build, with onboarding of thousands of patients in the US and Canada in Q1.
Advanced Therapy Connect: Launched a provider ordering solution for cell and gene therapy products to ensure seamless patient care.
Market Expansion: Cardinal Health is expanding its patient access to the Kangaroo OMNI Enteral Feeding Pump globally throughout the fiscal year.
Geographic Expansion: The acquisition of Integrated Oncology Network will enhance Cardinal Health's footprint across 10 states.
Operational Efficiency: Achieved multi-year highs in productivity and service levels during Q1.
Cost Management: The company is managing through external challenges with minimal disruptions to service.
Supply Chain Resiliency: Expanded domestic syringe production in response to industry-wide disruptions.
Strategic Shift: Cardinal Health is focusing on simplification and core operational execution to enhance service delivery.
Guidance Update: Raised EPS guidance to a range of $7.75 to $7.90 and adjusted free cash flow outlook to $1 billion to $1.5 billion for fiscal '25.
Customer Transition Risks: The company faced challenges due to a large customer transition, which impacted financial results in the GMPD segment.
Health and Welfare Costs: Unanticipated health and welfare costs led to a decrease in GMPD segment profit, with a $17 million year-over-year increase in these costs.
Supply Chain Challenges: Increased manufacturing costs, including startup costs related to expanding domestic manufacturing, affected GMPD segment performance.
Regulatory and Economic Factors: The company anticipates potential impacts from regulatory changes, including the IRA, which could affect specialty drug volumes and pricing.
Competitive Pressures: The loss of lower-margin VA government distribution contracts may increase competitive pressures in the GMPD segment.
Raw Material Shortages: An industry-wide raw material shortage of Moly-99 is expected to impact Nuclear business volume and profitability in Q2.
Tariff Impacts: Upcoming tariffs on products sourced from China may lead to increased costs, affecting pricing and margins across the industry.
Acquisition of Integrated Oncology Network: Cardinal Health reached an agreement to acquire Integrated Oncology Network for $1.1 billion, aimed at improving cancer care in underserved communities.
GMPD Improvement Plan: The GMPD team continues to execute on the GMPD Improvement Plan, focusing on enhancing supply chain resiliency and operational efficiency.
Investment in CapEx: Cardinal Health invested $90 million in CapEx to drive organic growth.
Shareholder Return: Returned approximately $500 million to shareholders through share repurchases and dividends, including a $375 million accelerated share repurchase program.
EPS Guidance: Raised EPS guidance for fiscal '25 to a range of $7.75 to $7.90, reflecting improved Pharma segment profit expectations.
Free Cash Flow Guidance: Adjusted free cash flow outlook for fiscal '25 to a range of $1 billion to $1.5 billion.
Pharma Revenue Outlook: Improved revenue outlook for Pharmaceutical and Specialty Solutions to a decline of 2% to 4%, with fiscal '25 revenue growth at the midpoint expected to be between 18% to 20%.
GMPD Segment Profit Guidance: Updated GMPD segment profit outlook to a range of $140 million to $175 million, primarily due to unexpected health and welfare costs.
Other Segment Growth Guidance: Reiterated prior guidance of 10% to 12% revenue growth for Other businesses and approximately 10% segment profit growth.
Dividends Returned to Shareholders: Approximately $500 million returned to shareholders through share repurchase and dividends, including a $375 million accelerated share repurchase program.
Share Repurchase Program: Executed an early accelerated share repurchase program, returning approximately $500 million to shareholders.
The earnings report shows strong financial performance with a 13% EPS growth, a 21% increase in operating earnings, and robust cash flow. The share repurchase program indicates confidence in the company's stock. Despite flat revenue, adjusted figures show significant growth. The Q&A reveals resilience against macroeconomic factors and effective cost management. However, management's lack of clarity on some issues slightly tempers optimism. Overall, the positive financial metrics and strategic share repurchase outweigh the concerns, suggesting a positive stock price movement.
The earnings call presents a mixed but overall positive outlook. Despite a 4% revenue decrease due to customer transition, organic growth is strong at 15%. EPS growth is solid at 9%, and gross margins have improved. Share repurchase and dividend plans are robust, and specialty business growth is promising. However, raw material shortages and economic factors pose risks. The Q&A reveals confidence in handling these challenges, with management raising guidance due to strong demand. The positive aspects outweigh the negatives, suggesting a positive stock price reaction.
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
